Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Omeros Corporation (United States) | Researchclopedia

Back to institutions

Omeros Corporation (United States)

Seattlecompany

188

Works

42,544

Citations

99

h-index

Top Research Topics

Complement system in diseases Immunotherapy and Immune Responses Immune Cell Function and Interaction

Top Researchers

Elı́as Campo Università Cattolica del Sacro Cuore

1,565 works165,523 citationsh-index: 173

Recent Research

Activation of the Lectin Pathway Drives Persistent Complement Dysregulation in Long <scp>COVID</scp>

Samuel B. K. Keat,Priyanka Khatri,et al.

20260 citations

T-cell and B-cell Immunology

Cell Image Analysis Techniques

SARS-CoV-2 and COVID-19 Research

Monoclonal and Polyclonal Antibodies Research

COVID-19 Clinical Research Studies

Receptor Mechanisms and Signaling

Immune Response and Inflammation

RNA Interference and Gene Delivery

Renal Diseases and Glomerulopathies

Elaine S. Jaffe National Institutes of Health

1,158 works127,437 citationsh-index: 167

Randy D. Gascoyne

1,003 works106,962 citationsh-index: 152

Andreas Rosenwald University of Bonn

1,074 works101,072 citationsh-index: 135

Louis M. Staudt National Institutes of Health

801 works97,484 citationsh-index: 145

Joseph M. Connors Spinal Cord Injury BC

787 works90,709 citationsh-index: 120

Phosphodiesterase 7 inhibition reduces L-DOPA-induced dyskinesias in parkinsonian nonhuman primates

Brik Kochoian,Stefano Coletta,et al.

20250 citations

Narsoplimab Results in Excellent Survival in Adults and Children With Hematopoietic Cell Transplant Associated Thrombotic Microangiopathy ( <scp>TA</scp> ‐ <scp>TMA</scp> )

Michelle Long Schoettler,Sunil Kumar Pusarla,et al.

20254 citations

Narsoplimab Treatment for Hematopoietic Cell Transplant Associated Thrombotic Microangiopathy (TA-TMA) – Real World Outcomes from an Expanded Access Program

Michelle Long Schoettler,Narinder Nangia,et al.

20251 citations

Monotherapy Treatment with Zaltenibart (OMS906), an Alternative Pathway Masp-3 Inhibitor, Improved Key Hematologic Parameters in Patients with PNH with a Suboptimal Response to Ravulizumab: Interim Results from a Phase 2 Proof-of-Concept Study

Morag Griffin,Richard J. Kelly,et al.

20243 citations

Population Pharmacokinetics/Pharmacodynamics and Clinical Pharmacology of Zaltenibart (OMS906) in Healthy Subjects and Patients with PNH

W. Jason Cummings,Yi Li,et al.

20240 citations